SCHEMBL2009982

SCHEMBL2009982

COc1ccc(F)cc1-c1c(C)cc(C(C)N)cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 3/20 0.37
PGR P06401 3/20 0.37
NR3C2 P08235 1/20 0.37
AR P10275 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
ERN1 O75460 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
SLC9A1 P19634 2/20 0.37
CTSA P10619 3/20 0.36
CASR P41180 2/20 0.36
S1PR1 P21453 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
LRRK2 Q5S007 2/20 0.36
DPP4 P27487 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4971151 0.79 SLC9A1 (0.42) NR3C1PGRNR3C2ARAKR1C3
SCHEMBL2009504 0.79 CASR (0.49) NR3C1PGRNR3C2ERN1CASR
SCHEMBL2009918 0.79 CASR (0.49) NR3C1PGRNR3C2ERN1CASR
SCHEMBL8940603 0.73 ERN1 (0.51) NR3C1PGRNR3C2ARERN1
SCHEMBL23123201 0.72 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL5680284 0.72 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL10304909 0.72 S1PR1 (0.46) NR3C1PGRNR3C2ARERN1
SCHEMBL15455603 0.72 ERN1 (0.45) NR3C1PGRNR3C2ARERN1
SCHEMBL895659 0.71 CYP2D6 (0.49) SLC6A4
SCHEMBL669891 0.71 CYP2D6 (0.49) SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960365-B2 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2011-06-14 US disclosed
EP-1965785-A1 COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR N.V. Organon (NL) 2008-09-10 EP disclosed
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2007-06-28 US disclosed
WO-2007071638-A1 COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR N.V. ORGANON (NL) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor NR3C1, NR3C2, MC2R NR3C1 1/4885PGR 131/4885NR3C2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.